What time is the conference call scheduled to start?

The conference call will begin at 10 a.m. Eastern time on the same day as the results announcement.

How can the public access the conference call?

Investors and the public can access the live webcast of the conference call through a link posted on Lilly's investor relations website.

Will there be a replay available for the conference call?

A replay of the conference call will be available on Lilly's website following the live event.

What are some of the key health challenges that Eli Lilly is addressing?

Eli Lilly is focused on pioneering life-changing discoveries to address significant health challenges, including diabetes, obesity, Alzheimer's disease, immune disorders, and difficult-to-treat cancers.

Lilly confirms date and conference call for third-quarter 2024 financial results announcement

Q: When will Eli Lilly announce its third-quarter financial results?

Eli Lilly and Company will announce its third-quarter 2024 financial results on October 30, 2024.

10/16/24 10:00:00 AM ET

$LLY

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $LLY alert in real time by email

INDIANAPOLIS, Oct. 16, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) will announce its third-quarter 2024 financial results on Oct. 30, 2024. Lilly will also conduct a conference call that day with the investment community and media to further detail the company's financial performance.

The conference call will begin at 10 a.m. Eastern time. Investors, media and the general public can access a live webcast of the conference call through a link that will be posted on Lilly's website at https://investor.lilly.com/webcasts-and-presentations. A replay will also be available on the website following the conference call.

About Lilly

Lilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer's disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visit Lilly.com and Lilly.com/news or follow us on Facebook, Instagram and LinkedIn. F-LLY

Refer to:	Jordan Bishop; [email protected]; 317-374-1878 (Media)
	Joe Fletcher; [email protected]; 317-296-2884 (Investors)

View original content to download multimedia:https://www.prnewswire.com/news-releases/lilly-confirms-date-and-conference-call-for-third-quarter-2024-financial-results-announcement-302276899.html

SOURCE Eli Lilly and Company

Get the next $LLY alert in real time by email

Recent Analyst Ratings for

$LLY

Date	Price Target	Rating	Analyst
11/15/2024	$1000.00	Outperform	Wolfe Research
10/17/2024	$1100.00	Outperform	Bernstein
9/13/2024	$1060.00	Buy	Citigroup
8/12/2024	$1025.00	Hold → Buy	Deutsche Bank
2/21/2024	$820.00	Buy → Hold	DZ Bank
2/16/2024	$805.00 → $950.00	Overweight	Morgan Stanley
12/21/2023	$660.00 → $610.00	Buy → Outperform	Daiwa Securities
11/9/2023	$535.00	Hold	Deutsche Bank

More analyst ratings

Lilly confirms date and conference call for third-quarter 2024 financial results announcement

Chat with this insight

Q&A

When will Eli Lilly announce its third-quarter financial results?

What time is the conference call scheduled to start?

How can the public access the conference call?

Will there be a replay available for the conference call?

What are some of the key health challenges that Eli Lilly is addressing?

Recent Analyst Ratings for $LLY

$LLY Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Director Walker Karen was granted 303 shares, increasing direct ownership by 5% to 6,249 units (SEC Form 4)

Director Sulzberger Gabrielle was granted 316 shares, increasing direct ownership by 14% to 2,517 units (SEC Form 4)

Director Luciano Juan R was granted 323 shares, increasing direct ownership by 2% to 16,147 units (SEC Form 4)

$LLY Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Eli Lilly and Company

SEC Form SC 13G/A filed by Eli Lilly and Company (Amendment)

SEC Form SC 13G/A filed by Eli Lilly and Company (Amendment)

$LLY Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Wolfe Research initiated coverage on Eli Lilly with a new price target

Bernstein initiated coverage on Eli Lilly with a new price target

Citigroup resumed coverage on Eli Lilly with a new price target

$LLY Market Insights

Live Market Insights

Here's How Much You Would Have Made Owning Eli Lilly and Co Stock In The Last 15 Years

Eli Lilly and Novo Nordisk shares are trading lower after competitor Viking announced the advancement of its obesity candidate.

Elon Musk Agrees With Former Executive Who Thinks 'Everyone' Has 'Strong' Opinions On Tesla Unlike In The Case Of Eli Lilly And LVMH

$LLY Leadership Updates

Live Leadership Updates

Asha Therapeutics Awarded Barnett Drug Development Grant by the ALS Association to Advance Novel Intra-Molecular Glue Inhibitor of SARM1 to Clinic and Announces Appointment of Disarm Therapeutics' Founders to Company's Scientific Advisory Board

Lilly appoints Lucas Montarce as executive vice president and chief financial officer

Lilly announces retirement of Marschall S. Runge from its Board of Directors

$LLY Press Releases

Fastest customizable press release news feed in the world

Verge Genomics Announces Milestones in Collaboration with Lilly to Discover and Develop Novel Treatments for ALS

Lilly announces changes on board of directors

Lilly's muvalaplin lowered lipoprotein(a) levels in adults with high risk for cardiovascular events by up to 85% at highest tested dose

$LLY FDA approvals

Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

May 31, 2024 - FDA Roundup: May 31, 2024

May 7, 2024 - FDA Roundup: May 7, 2024

December 5, 2023 - FDA Roundup: December 5, 2023

$LLY SEC Filings

Eli Lilly and Company filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

SEC Form 10-Q filed by Eli Lilly and Company

Eli Lilly and Company filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

$LLY Financials

Live finance-specific insights

Lilly reports Q3 2024 financial results highlighted by strong volume-driven revenue growth from New Products

Lilly declares fourth-quarter 2024 dividend

Lilly confirms date and conference call for third-quarter 2024 financial results announcement

Recent Analyst Ratings for
$LLY

$LLY
Insider Trading

$LLY
Large Ownership Changes

$LLY
Analyst Ratings

$LLY
Market Insights

$LLY
Leadership Updates

$LLY
Press Releases

$LLY
FDA approvals

$LLY
SEC Filings

$LLY
Financials